¿Qué quieres aprender?

Máster en Biotecnologia con mención en International Business Administration (VI Edición) ...

Máster en Biotecnologia con mención en International Business Administration (VI Edición) - Barcelona

Universidad de Barcelona and Biotechnology Business Institute

Máster presencial

Barcelona


12.900

Duración : 1 Año

¿Quieres hablar con un asesor sobre este curso?

Sedes

Localización

Fecha inicio

Barcelona

Objetivos

The objective of the program is to acquire the knowledge in setting up and manage biotech-based companies in drug discovery and understand knowledge transfer and capital increases in early stage preclinical and clinical phases. The main skills and topics are related with financial statements, entrepreneurship and business models, financial valuation, venture funds, financing rounds and international relationships within the different stakeholders in life sciences sector.

A quién va dirigido

The program is design for MSc and PhD with and with a high interest in science, willing to develop their career out the laboratory and the bench, in different management positions along the biopharmaceutical sector such as in biotechnology-based companies, investment funds or technology transfer offices. The program is design for scientifics interested in acquiring a financial background and a global understanding in how the biotechnology companies develop their compounds oriented to drug discovery.

Requisitos

Bachelor degree or PhD in Lifesciences; Biotechnology, Biochemistry, Bioengineering, Pharmacy, Biologist, etc.

Temario completo de este curso

GLOBAL ECOSYSTEM IN DRUG DISCOVERY
I. Biotechnology sector & Pharmaceutical industry
II. Intellectual Property and Strategy
III. Add Value & Unmet Need in Innovation
IV. Market Analysis Competitors in Development
V. Early Stage Licensing Agreements
VI. Public Funding for start-ups and spin-offs
VII. Early Market Access and Health Economics
VIII. Venture Funds and Late Stage Licensing

SCIENTIFIC AND REGULATORY DEVELOPMENT
I. Drug Discovery Process II. Target Product Profile (TPP)
III. Stakeholders in clinical and preclinical developments
IV. Preclinical and Clinical Development of Chemical compounds
V. Preclinical and Clinical Development of Biologic compounds
VI. Clinical Trial Design, Planification and Costs
VII. QXP’s and GMP’s during drug developments
VIII. Drug Registration Dossier for Approval FDA/EMA

PROFESIONAL AND PERSONAL DEVELOPMENT
I. Team Building
II. Leadership
III. Negotiation
IV. Management

BIOTECHNOLOGY BASED COMPANIES
I. Financial Statements
II. Financial Ratios and Analysis
III. Financial Management
IV. Debt Management
V. Project Management Fundamentals
VI. Public and Private Funding
VII. Venture Valuation and Financial Models
VIII. Early Market Access and Pricing
IX. Strategic Marketing vs Operational
X. Medical Marketing

VENTURE CAPITAL AND FUNDING
I. Private and Public Companies Valuation
II. Venture Financial Models
III. Capital Increase Strategy
IV. Due Diligence and Negotiations
V. Shareholders Agreement
VI. Exist Strategy and ROI
VII. Deal Structure and Milestones
VIII. Initial Public Offers IPO’s
IX. M&A vs Late Stage Licensing
X. Strategic alliances
Ver más